Research programme: sulforafan analogues - Evgen Pharma/CSIC/University of Seville
Latest Information Update: 01 Apr 2016
At a glance
- Originator CSIC; Evgen Pharma; Universidad de Sevilla
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation
Most Recent Events
- 11 Nov 2013 Early research in Inflammation in Spain and United Kingdom (unspecified route)
- 11 Nov 2013 Early research in Cancer in Spain and United Kingdom (unspecified route)